Method for treating drug-induced constipation

US 20030073746A1
Filed: 05/01/2002
Published: 04/17/2003
Est. Priority Date: 05/02/2001
Status: Active Grant

First Claim

Patent Images

1. A method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it.

View all claims

8 Assignments

Timeline View

Assignment View

0 Petitions

Accused Products

Abstract

Provided is a method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it. According to the present invention, a strong antagonistic action against drug-induced constipation can be obtained without substantially losing the main effect of the drug.

Citations

13 Claims

1. A method for treating drug-induced constipation comprising a step of administering an effective amount of a 15-keto-prostaglaindin compound to a subject suffering from drug-induced constipation or a subject having a strong possibility of suffering from it.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- - 2. The method of claim 1, wherein a 15-keto-prostaglaindin compound is the one represented by the general formula (I):
  - 3. The method of claim 1, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-prostaglandin compound.
  - 4. The method of claim 1, wherein the 15-keto-prostaglaindin compound is a 15-keto-16-mono- or di-halogen-prostaglaindin compound.
  - 5. The method of claim 1, wherein the 15-keto-prostaglaindin compound is a 13,14-dihydro-15-keto-16-mono- or di-halogen-prostaglaindin compound.
  - 6. The method of claim 1, wherein the 15-keto-prostaglaindin compound is a 15-keto-16-mono- or di-fluoro-prostaglaindin compound.
  - 7. The method of claim 1, wherein the 15-keto-prostaglandin compound is a 13,14-dihydro-15-keto-16-mono- or di-fluoro-prostaglaindin compound.
  - 8. The method of claim 1, wherein the 15-keto-prostaglaindin compound is a 15-keto-prostaglandin E compound.
  - 9. The method of claim 1, wherein the 15-keto-prostaglandin compound is 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E₁.
  - 10. The method of claim 1, wherein the drug inducing constipation is an opioid compound.
  - 11. The method of claim 10, wherein the opioid compound is a morphine compound or a codeine compound.
  - 12. The method of claim 1, wherein the drug inducing constipation is an anticholinergic drug.
  - 13. The method of claim 12, wherein the anticholinergic drug is a tricyclic antidepressant.

Specification

Resources

Litigation Campaign Assessment

Current Assignee
Sucampo AG (Mallinckrodt plc)
Original Assignee
Sucampo AG (Mallinckrodt plc)
Inventors
Ueno, Ryuji

Granted Patent

US 6,982,283 B2
Time in Patent Office

Days
Field of Search
US Class Current

514/573
CPC Class Codes

A61K 2300/00   Mixtures or combinations of...

A61K 31/485   Morphinan derivatives, e.g....

A61K 31/557   Eicosanoids, e.g. leukotrie...

A61K 31/5575   having a cyclopentane, e.g....

A61P 1/10   Laxatives

Method for treating drug-induced constipation

First Claim

8 Assignments

0 Petitions

Accused Products

Abstract

Citations

13 Claims

Specification

Solutions

Use Cases

Quick Links

Method for treating drug-induced constipation

First Claim

8 Assignments

Subscription Required

Subscription Required

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

Citations

13 Claims

Specification

Subscription Required

Solutions

Use Cases

Quick Links